Mineralys Therapeutics (MLYS)Director bought ~$3.5M
Brian Taylor Slingsby, Director at Mineralys Therapeutics, bought ~$3.5M of Mineralys Therapeutics shares.
- ~$3.5M
- Approx. value · 259K sh @ $13.50
- 8.9M
- Holds after · shares reported
- Traded
- Mar 13, 2025
- Filed
- Apr 25, 2025
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Jan 13, 2025Insider · 2 peopleInsiders: 3 sales (~$264K)
- Mar 13, 2025 · this disclosureInsiderDirector purchased ~$3.5M of MLYS shares in the open market
What came next
- Mar 13, 2025Insider · 3 peopleInsiders: 3 purchases (~$33.7M)
- Apr 1, 2025Insider · 1 personInsiders: 3 sales (~$879K)
- Apr 11, 2025Insider · 2 peopleInsiders: 2 sales (~$316K)
- Apr 14, 2025Insider · 1 personInsiders: 2 sales (~$165K)
- May 14, 2025InsiderOfficer sold ~$174K of MLYS shares in the open market
- Jun 13, 2025InsiderOfficer sold ~$166K of MLYS shares in the open market
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Mineralys Therapeutics
For Mineralys Therapeutics, OQRO holds 2 insider filings (SEC Form 4 or Form 144) and 3 fund holdings reports (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its MLYS page.
Other recent filings by Brian Taylor Slingsby, Director
The full history of Brian Taylor Slingsby, Director is on the profile page.
How this filing works
Other disclosures at Mineralys Therapeutics
- SEC Form 4Oct 2, 2026
- SEC Form 4Sep 25, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRMay 15, 2026
Everything OQRO holds on this company is on its MLYS page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO Pro is a paid subscription. You see the price before you pay
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data